Natarajan Sethuraman - Mar 1, 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: Chief Scientific Officer
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Stock symbol: TRDA
Transactions as of: Mar 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/3/2022, 03:10 PM
Previous filing: Oct 28, 2021
Next filing: Jul 6, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Award	$0	+11.6K	+8%	$0.00	156K	Mar 1, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRDA	Stock Option (Right to Buy)	Award	$0	+69.5K		$0.00	69.5K	Mar 1, 2022	Common stock	69.5K	$11.57	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
F2	Consists of (i) 118,836 shares of common stock, (ii) 25,926 shares of restricted common stock issued upon early exercise of stock options, and (iii) 11,588 RSUs reported in this transaction.
F3	25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026.